Establishment and characterization of an EBNA-negative human lymphoma cell line (BHL-89)

I. Palyi, T. Fleischmann, V. Palyi, D. Duabner, T. Raposa, K. Pálóczi, M. Benczur, L. Gergely, O. Csuka, M. Bak

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. The aim of the work was to establish human malignant lymphomas in culture, in order to study the biological characteristics and drug sensitivity of lymphomas of human lymphoid origin. Materials and Methods. Lymph nodes of patients were explanted and kept in cultures using conventional tissue culture methods. Cytogenetic methods were used for karyotype analysis. Clonogenic assay was applied to test drug sensitivity. The tumorigenic capacity of the cells was determined by inoculating them into immunosuppressed mice. Immunological and other markers were examined with conventional techniques. Results. A cell line, BHL-89, was established in culture from a patient with B-cell type non-Hodgkin's malignant lymphoma. Cells started to grow after a few days without a feeder layer in stationary suspension. The population doubling time was 48 h. The cells were hyperploid, and nonrandom aberrations were +1, -15, +14q+. Cloning efficiency in soft agar was found to be as high as 50-60%. The cells expressed markers characteristic of early B cells. The BHL-89 cells were Epstein-Barr nuclear antigen (EBNA) negative. They produced tumors when 107 cells were injected into immunosuppressed mice. The cells were sensitive to dibromodulcitol (Elobromol), an alkylating antitumor drug, and resistant to the phorbol ester TPA. Conclusions. The established EBNA-negative BHL-89 cell line has a few unique characteristics, e.g. rapid establishment without feeder cells, origin from the lymph node of an adult patient, high clonogenicity in soft agar, and resistance to TPA. The cell line is suitable for studying the nature of B lymphomas and testing compounds against lymphoproliferative disorders.

Original languageEnglish
Pages (from-to)206-211
Number of pages6
JournalHaematologica
Volume80
Issue number3
Publication statusPublished - 1995

Fingerprint

Nuclear Antigens
Lymphoma
Cell Line
Feeder Cells
Agar
Mitolactol
B-Lymphocytes
Lymph Nodes
Lymphoproliferative Disorders
Phorbol Esters
Karyotype
Cytogenetics
Pharmaceutical Preparations
Antineoplastic Agents
Non-Hodgkin's Lymphoma
Organism Cloning
Suspensions
Population

Keywords

  • chromosome markers
  • drug sensitivity
  • EBV
  • human B cell line
  • tumorigenicity

ASJC Scopus subject areas

  • Hematology

Cite this

Palyi, I., Fleischmann, T., Palyi, V., Duabner, D., Raposa, T., Pálóczi, K., ... Bak, M. (1995). Establishment and characterization of an EBNA-negative human lymphoma cell line (BHL-89). Haematologica, 80(3), 206-211.

Establishment and characterization of an EBNA-negative human lymphoma cell line (BHL-89). / Palyi, I.; Fleischmann, T.; Palyi, V.; Duabner, D.; Raposa, T.; Pálóczi, K.; Benczur, M.; Gergely, L.; Csuka, O.; Bak, M.

In: Haematologica, Vol. 80, No. 3, 1995, p. 206-211.

Research output: Contribution to journalArticle

Palyi, I, Fleischmann, T, Palyi, V, Duabner, D, Raposa, T, Pálóczi, K, Benczur, M, Gergely, L, Csuka, O & Bak, M 1995, 'Establishment and characterization of an EBNA-negative human lymphoma cell line (BHL-89)', Haematologica, vol. 80, no. 3, pp. 206-211.
Palyi I, Fleischmann T, Palyi V, Duabner D, Raposa T, Pálóczi K et al. Establishment and characterization of an EBNA-negative human lymphoma cell line (BHL-89). Haematologica. 1995;80(3):206-211.
Palyi, I. ; Fleischmann, T. ; Palyi, V. ; Duabner, D. ; Raposa, T. ; Pálóczi, K. ; Benczur, M. ; Gergely, L. ; Csuka, O. ; Bak, M. / Establishment and characterization of an EBNA-negative human lymphoma cell line (BHL-89). In: Haematologica. 1995 ; Vol. 80, No. 3. pp. 206-211.
@article{0ce9824231fd404693dca688fb5ce5d1,
title = "Establishment and characterization of an EBNA-negative human lymphoma cell line (BHL-89)",
abstract = "Background. The aim of the work was to establish human malignant lymphomas in culture, in order to study the biological characteristics and drug sensitivity of lymphomas of human lymphoid origin. Materials and Methods. Lymph nodes of patients were explanted and kept in cultures using conventional tissue culture methods. Cytogenetic methods were used for karyotype analysis. Clonogenic assay was applied to test drug sensitivity. The tumorigenic capacity of the cells was determined by inoculating them into immunosuppressed mice. Immunological and other markers were examined with conventional techniques. Results. A cell line, BHL-89, was established in culture from a patient with B-cell type non-Hodgkin's malignant lymphoma. Cells started to grow after a few days without a feeder layer in stationary suspension. The population doubling time was 48 h. The cells were hyperploid, and nonrandom aberrations were +1, -15, +14q+. Cloning efficiency in soft agar was found to be as high as 50-60{\%}. The cells expressed markers characteristic of early B cells. The BHL-89 cells were Epstein-Barr nuclear antigen (EBNA) negative. They produced tumors when 107 cells were injected into immunosuppressed mice. The cells were sensitive to dibromodulcitol (Elobromol), an alkylating antitumor drug, and resistant to the phorbol ester TPA. Conclusions. The established EBNA-negative BHL-89 cell line has a few unique characteristics, e.g. rapid establishment without feeder cells, origin from the lymph node of an adult patient, high clonogenicity in soft agar, and resistance to TPA. The cell line is suitable for studying the nature of B lymphomas and testing compounds against lymphoproliferative disorders.",
keywords = "chromosome markers, drug sensitivity, EBV, human B cell line, tumorigenicity",
author = "I. Palyi and T. Fleischmann and V. Palyi and D. Duabner and T. Raposa and K. P{\'a}l{\'o}czi and M. Benczur and L. Gergely and O. Csuka and M. Bak",
year = "1995",
language = "English",
volume = "80",
pages = "206--211",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "3",

}

TY - JOUR

T1 - Establishment and characterization of an EBNA-negative human lymphoma cell line (BHL-89)

AU - Palyi, I.

AU - Fleischmann, T.

AU - Palyi, V.

AU - Duabner, D.

AU - Raposa, T.

AU - Pálóczi, K.

AU - Benczur, M.

AU - Gergely, L.

AU - Csuka, O.

AU - Bak, M.

PY - 1995

Y1 - 1995

N2 - Background. The aim of the work was to establish human malignant lymphomas in culture, in order to study the biological characteristics and drug sensitivity of lymphomas of human lymphoid origin. Materials and Methods. Lymph nodes of patients were explanted and kept in cultures using conventional tissue culture methods. Cytogenetic methods were used for karyotype analysis. Clonogenic assay was applied to test drug sensitivity. The tumorigenic capacity of the cells was determined by inoculating them into immunosuppressed mice. Immunological and other markers were examined with conventional techniques. Results. A cell line, BHL-89, was established in culture from a patient with B-cell type non-Hodgkin's malignant lymphoma. Cells started to grow after a few days without a feeder layer in stationary suspension. The population doubling time was 48 h. The cells were hyperploid, and nonrandom aberrations were +1, -15, +14q+. Cloning efficiency in soft agar was found to be as high as 50-60%. The cells expressed markers characteristic of early B cells. The BHL-89 cells were Epstein-Barr nuclear antigen (EBNA) negative. They produced tumors when 107 cells were injected into immunosuppressed mice. The cells were sensitive to dibromodulcitol (Elobromol), an alkylating antitumor drug, and resistant to the phorbol ester TPA. Conclusions. The established EBNA-negative BHL-89 cell line has a few unique characteristics, e.g. rapid establishment without feeder cells, origin from the lymph node of an adult patient, high clonogenicity in soft agar, and resistance to TPA. The cell line is suitable for studying the nature of B lymphomas and testing compounds against lymphoproliferative disorders.

AB - Background. The aim of the work was to establish human malignant lymphomas in culture, in order to study the biological characteristics and drug sensitivity of lymphomas of human lymphoid origin. Materials and Methods. Lymph nodes of patients were explanted and kept in cultures using conventional tissue culture methods. Cytogenetic methods were used for karyotype analysis. Clonogenic assay was applied to test drug sensitivity. The tumorigenic capacity of the cells was determined by inoculating them into immunosuppressed mice. Immunological and other markers were examined with conventional techniques. Results. A cell line, BHL-89, was established in culture from a patient with B-cell type non-Hodgkin's malignant lymphoma. Cells started to grow after a few days without a feeder layer in stationary suspension. The population doubling time was 48 h. The cells were hyperploid, and nonrandom aberrations were +1, -15, +14q+. Cloning efficiency in soft agar was found to be as high as 50-60%. The cells expressed markers characteristic of early B cells. The BHL-89 cells were Epstein-Barr nuclear antigen (EBNA) negative. They produced tumors when 107 cells were injected into immunosuppressed mice. The cells were sensitive to dibromodulcitol (Elobromol), an alkylating antitumor drug, and resistant to the phorbol ester TPA. Conclusions. The established EBNA-negative BHL-89 cell line has a few unique characteristics, e.g. rapid establishment without feeder cells, origin from the lymph node of an adult patient, high clonogenicity in soft agar, and resistance to TPA. The cell line is suitable for studying the nature of B lymphomas and testing compounds against lymphoproliferative disorders.

KW - chromosome markers

KW - drug sensitivity

KW - EBV

KW - human B cell line

KW - tumorigenicity

UR - http://www.scopus.com/inward/record.url?scp=0029145040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029145040&partnerID=8YFLogxK

M3 - Article

C2 - 7672713

AN - SCOPUS:0029145040

VL - 80

SP - 206

EP - 211

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 3

ER -